Dacou-Voutetakis C, Karidis N
First Pediatric Department, Athens University, Greece.
Ann N Y Acad Sci. 1993 May 28;687:250-4. doi: 10.1111/j.1749-6632.1993.tb43873.x.
Eight children with congenital adrenal hyperplasia and late initiation of corticosteroid treatment are included in the present study. Four of them received LHRHa treatment for the arrest of central precocious puberty, while the other four served as controls. The administration of LHRHa was effective in arresting the manifestations of puberty. The final height in the LHRHa-treated group was 158.2 +/- 7.3 cm (SDS -1.1 +/- 0.5) and did not differ from the target height of 158.9 +/- 6.5 cm (SDS -1.1 +/- 0.2), while the final height in the controls was 153 +/- 11 cm, a value significantly lower than their target height of 164.5 +/- 8.3 (SDS -0.6 +/- 0.7) with p < 0.05. The data showed that LHRHa is effective in arresting central precocious puberty and appears to improve final height, bringing it closer to that expected from the genetic potentials.
本研究纳入了8名先天性肾上腺皮质增生症且皮质类固醇治疗起始较晚的儿童。其中4名接受促性腺激素释放激素类似物（LHRHa）治疗以抑制中枢性性早熟，另外4名作为对照。LHRHa治疗在抑制青春期表现方面有效。LHRHa治疗组的最终身高为158.2±7.3厘米（标准差评分[SDS]为-1.1±0.5），与目标身高158.9±6.5厘米（SDS为-1.1±0.2）无差异，而对照组的最终身高为153±11厘米，该值显著低于其目标身高164.5±8.3厘米（SDS为-0.6±0.7），p<0.05。数据表明，LHRHa在抑制中枢性性早熟方面有效，且似乎能改善最终身高，使其更接近遗传潜力所预期的身高。
